Sensitizing Tumours To Immunotherapy: Development Of An RNA-based Therapeutic For Pancreatic Adenocarcinoma That Targets The Immunosuppressive Tumour Microenvironment.
Funder
National Health and Medical Research Council
Funding Amount
$192,347.00
Summary
The blood vessels of tumours are highly abnormal resulting in leakiness and hypoxia within the microenvironment. These abnormalities contribute both to the pathology and also to resistance to treatment. We have developed a new drug that is able to inhibit vascular leak, better the response to therapies and improve disease outcome. This work will generate essential data for the development of this drug towards Clinical Trials through interaction with International Pharma.
The Role Of Angiopoietin-1 In The Self-renewal And Metastasis Of Prostate Cancer Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$558,742.00
Summary
Bone metastasis occurs in more than 80% of cases of advanced prostate cancer (PCa), and is the major cause of morbidity and mortality in PCa patients. Understanding why PCa cells preferentially metastasize to bone may lead to the the development of novel therapy for inhibiting PCa metastasis. This project will study how the bone cell-secreted protein angiopoietin-1 promotes the metastasis of PCa cells to bone and whether inactivation of this protein can inhibit PCa bone metastasis.
Regulation Of Breast Cancer Metastasis By MiR-193b And MiR-342-3p
Funder
National Health and Medical Research Council
Funding Amount
$581,537.00
Summary
When breast cancer spreads to other organs, it results in high morbidity and mortality. MicroRNAs are a class of genes that control the expression of other genes, some of which are involved in the spread of cancer. In this project we will examine the function of two microRNA species that we have found to be associated with breast cancer spread. The anticipated outcome is a better knowledge of the genes that control cancer spread and the identification of new molecular targets for therapy.